Examining retinal cell stress in age-related macular degeneration
Retinal Fundus Flavoprotein Fluorescence in Age Related Macular Degeneration: New Insights From Multimodal Imaging
This study is testing if a new imaging technique can help find early signs of stress in the retina for people aged 50 and older with age-related macular degeneration.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | University of Wisconsin, Madison Academic / other |
| Locations | 1 site (Madison, Wisconsin) |
| Trial ID | NCT06381596 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to investigate whether areas of mitochondrial distress in the retina, as seen through fundus flavoprotein fluorescence (FPF), correlate with anatomical disease areas identified through standard imaging techniques. Participants, aged 50 and older with geographic atrophy due to age-related macular degeneration, will undergo FPF imaging using the OcuMet Beacon system alongside fundus autofluorescence imaging. The study seeks to identify potential areas of concern in the retina before symptoms manifest, enhancing early detection and intervention strategies.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 50 and older with a confirmed diagnosis of geographic atrophy due to age-related macular degeneration.
Not a fit: Patients with neovascular age-related macular degeneration or significant media opacity that prevents adequate imaging may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection of geographic atrophy in patients with age-related macular degeneration.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in using advanced imaging techniques for early detection of retinal diseases.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 50 years or older and may be either male or female of any race * Established diagnosis of GA due to AMD * GA characteristics: GA area of between 1.25 mm² and 23 mm², with seventy percent of eyes having GA area ranging from 2.5 mm2 to 17.5 mm2. GA may be unifocal or multifocal. GA may be subfoveal or extrafoveal, with twenty-five percent of eyes having subfoveal GA. The presence of concurrent peripapillary atrophy will not exclude subjects from participation * Willing to participate as evidenced by signing the written informed consent Exclusion Criteria: * Unable to tolerate ophthalmic imaging * Presence of neovascular AMD on OCT as confirmed by an ophthalmologist * Presence of significant media opacity preventing adequate retinal imaging * Presence of concurrent retinal disease which may confound assessment
Where this trial is running
Madison, Wisconsin
- Department of Ophthalmology and Visual Sciences — Madison, Wisconsin, United States (Recruiting)
Study contacts
- Principal investigator: Mihai Mititelu, MD, MPH — University of Wisconsin, Madison
- Study coordinator: Angie Adler
- Email: amadler1@wisc.edu
- Phone: 608-265-7557
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.